Revenue (Quarterly)

Revenue: The sum of all revenue fields included for a company's operating activities.

Blueprint Medicines Corporation (BPMC) had Revenue of $149.41M for the most recently reported fiscal quarter, ending 2025-03-31.

Quarterly Annual

Figures for fiscal quarter ending 2025-03-31

Income Statement Financials
Revenue	$149.41M
Net Income	$0.50M
Cost of Goods Sold	$2.80M
Gross Profit	$146.61M
Operating Expenses	$190.50M
Operating Income	$-41.09M
Non-Operating Income/Expense	$42.37M
Pre-Tax Income	$1.28M
Normalized Pre-Tax Income	$1.28M
Income after Taxes	$0.50M
Income from Continuous Operations	$0.50M
Consolidated Net Income/Loss	$0.50M
Normalized Income after Taxes	$0.50M
EBIT	$-41.09M
EBITDA	$-39.96M
Weighted-Average Shares Outstanding (Basic)	64.10M
Weighted-Average Shares Outstanding (Diluted)	66.53M
Earnings per Share (EPS) (Basic)	$0.01
Earnings per Share (EPS) (Diluted)	$0.01
Balance Sheet Financials
Current Assets	$702.07M
Property, Plant, and Equipment	$36.05M
Long-Term Assets	$493.54M
Total Assets	$1.20B
Current Liabilities	$250.58M
Long-Term Debt	$343.95M
Long-Term Liabilities	$602.89M
Total Liabilities	$853.47M
Common Equity	$342.13M
Tangible Shareholders Equity	$342.13M
Shareholders Equity	$342.13M
Common Shares Outstanding	64.56M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$-54.48M
Cash Flow from Investing Activities	$65.08M
Cash Flow from Financial Activities	$9.19M
Beginning Cash	$113.64M
End Cash	$134.09M
Increase/Decrease in Cash	$20.45M
Stock-Based Compensation	$29.06M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	2.80
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	0.50
Debt to Equity Ratio	1.13
Gross Margin	98.12%
Operating Margin	-27.50%
EBIT Margin	-27.50%
EBITDA Margin	--
Pre-Tax Profit Margin	0.86%
Profit Margin	0.33%
Free Cash Flow	$-56.31M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.12
Inventory Turnover	0.22
Receiveable Turnover	1.87
Days Sales in Receivables	48.07
Return on Equity	0.14%
Return on Tangible Equity	0.14%
Return on Assets	0.04%
Return on Investments	0.07%
Book Value Per Share	$5.30
Free Cash Flow per Share	$-0.85
Operating Cash Flow per Share	$-0.82

Data from Zacks Investment Research, Inc.